Med-Fine Capital

Med-Fine Capital is a Shanghai-based healthcare venture investor focusing on precision medicine and next-generation diagnostics, with broader exposure to biotech across Series A and Series B rounds. The firm operates as a specialist rather than a generalist platform, and the sub-vertical mix suggests a thesis aligned with the rise of molecular diagnostics, companion testing, and therapeutic platforms tied to specific patient populations. Limited public information about the named partner team, fund vintages, and detailed portfolio is available in English-language sources, which is typical for healthcare-focused Chinese venture firms operating primarily in the domestic ecosystem.

Check sizes range from 5 million to 25 million dollars at Series A and Series B, deployed when companies have validated technical proof points and are scaling into clinical milestones, regulatory submissions, or commercial pilots. Geography centers on China with Shanghai as the operating base, situating the firm close to a dense cluster of biotech and diagnostics companies. Founders building outside the Chinese clinical and regulatory environment will find limited fit, since the firm’s value is partly about navigating that local ecosystem.

The approach is well suited to founders building diagnostics platforms, precision medicine therapeutics, or related life sciences tools with clear China-market ambitions. Those needing a global syndicate lead, broad consumer-facing brand support, or expertise in non-healthcare sectors should look elsewhere. Initial conversations should cover the company’s regulatory strategy in China, the realism of clinical or commercial milestones the round will fund, and what Med-Fine offers operationally beyond capital, particularly around hospital partnerships, CRO relationships, and downstream financing pathways.